New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
05:55 EDTPFE, IGTStocks with implied volatility movement; IGT PFE
Stocks with implied volatility movement; International Game (IGT) 17, Pfizer (PFE) 19 according to iVolatility.
News For IGT;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
12:30 EDTPFEOn The Fly: Top stock stories at midday
Stocks on Wall Street were higher at midday after crossing back and forth across the flat line during morning trading, much like Apple (AAPL) shares, which were searching for direction despite the company's report last night having topped expectations on several measures, including revenue, profits, iPhone unit sales and capital return plans. ECONOMIC EVENTS: In the U.S., the Case Shiller 20-city home price index rebounded 0.93% on a seasonally adjusted basis in February, versus expectations for it to be up 0.7% on a month-over-month basis. The Conference Board's consumer confidence index dropped 6.2 points to 95.2 in April, versus expectations for it to have risen to 102.2. The Richmond Fed manufacturing index rose to -3 in April, versus expectations for a reading of -2. COMPANY NEWS: Shares of Apple were little changed near noon after the company last night reported March quarter earnings and sales well above expectations and boosted its shares buyback program to $140B from $90B and quarterly dividend by 11% to 52c. FBR Capital called the quarter “Picasso-like,” while Brian White at Cantor Fitzgerald upped his price target on shares to $195. Less sanguine are analysts at Pacific Crest, Maxim and Deutsche Bank. Noted investor Carl Icahn said afterward that Apple is "still undervalued and misunderstood" and promised to put out another in-depth report on the company within two weeks... IBM (IBM) approved an 18% increase in its quarterly dividend to $1.30 per common share. MAJOR MOVERS: Among the notable gainers was Dow member Merck (MRK), which advanced 5% after its Q1 sales and EPS beat expectations. Two other big name, big revenue drugmakers slid after their earnings reports, as Bristol-Myers (BMY) declined 1% and Pfizer (PFE) fell 0.5%. Also lower following its earnings report was The Container Store (TCS), which declined about 16% after its results and outlook missed expectations. INDEXES: Near midday, the Dow was up 49.61, or 0.28%, to 18,087.58, the Nasdaq was up 9.87, or 0.2%, to 5,070.12, and the S&P 500 was up 3.98, or 0.19%, to 2,112.90.
07:33 EDTPFEHospira will not provide annual projections given merger agreement with Pfizer
07:33 EDTPFEHospira expects merger agreement with Pfizer to be completed in 2H15
Subscribe for More Information
07:12 EDTPFEPfizer lowers FY15 adjusted EPS view to $1.95-$2.05 from $2.00-$2.10
Consensus $2.07. Lowers FY15 revenue guidance to $44B-$46B from $44.5B-$46.5B, consensus $45.94B.
07:09 EDTPFEPfizer reports Q1 adjusted EPS 51c, consensus 49c
Subscribe for More Information
April 27, 2015
19:00 EDTIGTScientific Games says receives license termination notice from IGT
In a regulatory filing, Scientific Games (SGMS) reports that on April 21, it received notification from International Game Technology (IGT) purporting to terminate the license agreement between the two companies as a result of Scientific Games' alleged breach of licensing terms. The company notes that on June 13, 2014, it entered into a license agreement with IGT for its “ticket-in-ticket-out” cashless gaming technology. Prior to its acquisition by Scientific Games, Bally Technologies had also entered into a license agreement with IGT for the same technology. IGT believes that Scientific Games is in breach of its license agreement due to its use of license tags belonging to Bally instead of license tags issued to Scientific Games itself.
15:04 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
14:41 EDTPFEEarnings Watch: Pfizer up over 6% since its last earnings report
Subscribe for More Information
12:47 EDTPFEPfizer technical comments before earnings
Subscribe for More Information
09:03 EDTPFEChina Jo-Jo Drugstore signs incentive agreement with Pfizer subsidiary
China Jo-Jo Drugstores (CJJD) announced its subsidiary, Hangzhou Jiuzhou Grand Pharmacy Chain, has signed a new sales incentive agreement with Wyeth Pharmaceutical, a wholly owned subsidiary in China of Pfizer (PFE). The Agreement illustrated specific approaches and conditions of Jiuzhou Pharmacy's collaboration with Wyeth, including sales targets, promotional incentive to consumers, products and pricing methods. In return, Wyeth will fully support Jiuzhou Pharmacy with priority delivery, favorable purchase prices and promotional activities.
08:41 EDTPFETelegraph discusses potential takeover of GSK by Pfizer
Subscribe for More Information
06:19 EDTPFEPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 21, 2015
10:01 EDTPFEPfizer receives FDA breakthrough therapy designation for Xalkori
Subscribe for More Information
08:18 EDTPFEPain Therapeutics resumes responsibility for Remoxy
Subscribe for More Information
08:06 EDTPFEPfizer says Phase 3 inotuzumab ozogamicin study met first primary endpoint
Subscribe for More Information
April 20, 2015
08:02 EDTPFEMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
06:05 EDTPFEProvectus receives notice of allowance for PV-10 combined with other drugs
Subscribe for More Information
April 15, 2015
17:07 EDTIGTInternational Game subsidiary awarded $75M-$80M Minnesota Lottery contract
International Game subsidiary GTECH Corporation has entered into a contract with the Minnesota State Lottery to provide new lottery technology, an IP-communications network, multimedia displays, self-service products, and ongoing support services, following a competitive procurement. The 7.5 year integrated services contract with the Lottery contains three renewal options of one year each, or up to one renewal of three years, or any variation thereof. The company expects to receive approximately $75M-$80M in revenues over the base 7.5 year contract period, which runs through August 9, 2023.
08:04 EDTPFEPfizer: PALOMA-3 trial for IBRANCE met primary endpoint, trial stopped early
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use